<sup>Utility of plasma GFAP in differentiating neurodegenerative from non‐neurodegenerative cognitive impairment: A real‐world clinical experience</sup>
These findings support the utility of plasma GFAP, measured using a CMIA-based assay, in differentiating neurodegenerative from non-neurodegenerative cognitive impairments. Our real-world cohort analysis underscores the potential of pGFAP for broader clinical application beyond AD.
Authors
- M. Mesquida
- E. Bargay Pizarro (ORCID: https://orcid.org/0000-0002-9106-9489)
- L. Núñez Santos
- M. Santes Berto
- Ana García Martin
- Susana Tarongi Sanchez
- Marian Vives Crook (ORCID: https://orcid.org/0009-0009-5646-9039)
- Guillermo Amer Ferrer
- Daniel Morell García
Institutions
- Hospital Universitario Son Espases (ES)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_107570
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00